CDC director slams agency's response to COVID-19 pandemic

Rochelle P. Walensky, MD, MPH, director of the Centers for Disease Control and Prevention (CDC), slammed the agency for failing to respond to the COVID-19 pandemic quickly enough, according to a report from The New York Times.

Her remarks came during a senior staff meeting Aug. 17, with Walensky, formerly chief of the Division of Infectious Diseases at Massachusetts General Hospital and professor of medicine at Harvard Medical School, outlining a broad plan to reorganize the agency to meet public health needs and prevent future outbreaks. Facing heavy criticism for the CDC’s COVID-19 response, Walensky ordered an external review of the agency in April. Her message this week offered an unspecific plan to overhaul the CDC, released in a video to all CDC employees. 

“For 75 years, CDC. and public health have been preparing for Covid-19, and in our big moment, our performance did not reliably meet expectations,” she said Wednesday. “My goal is a new, public health, action-oriented culture at CDC that emphasizes accountability, collaboration, communication and timeliness.” 

Among the changes, Walensky announced the appointment of Mary K. Wakefield, a former Obama administration health official who will lead the CDC’s shift to a stronger public health focus, the NY Times reported. 

Walensky’s plan comes as the CDC is dealing with outbreaks of two other infectious diseases causing concern––monkeypox and polio.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.

Philips is recalling the software associated with its Mobile Cardiac Outpatient Telemetry devices after certain high-risk ECG events were never routed to trained cardiology technicians as intended. The issue, which lasted for two years, has been linked to more than 100 injuries.